TET2 and cancer: Despite numerous reports of somatic TET2 mutations in human cancer, mutant‐allele dosage remains underreported (Figure 3), in part due to the complex nature of biallelic mutations, which often involve compound heterozygosity, and the technical challenge of discerning whether multiple mutations are present on the same allele.